文献速递肝病消化道肿瘤与早癌

代偿期晚期慢性肝病丙型肝炎治愈后肝细胞癌风险分层

HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
PubMed 文献 · J Hepatol · 2021-12-03

在527例治疗前晚期慢性肝病且获得持续病毒学应答的患者中开发肝细胞癌风险分层算法,并在1500例代偿期晚期慢性肝病欧洲患者中验证。基于治疗后年龄、白蛋白、肝硬度测量,可选甲胎蛋白和饮酒量的简单算法可准确分层,约三分之二患者肝细胞癌风险低于每年1%。

要点

  • 代偿期晚期慢性肝病患者获得持续病毒学应答后,治疗后指标对肝细胞癌的区分能力优于治疗前值或变化值。
  • 基于治疗后甲胎蛋白、饮酒量(可选)、年龄、肝硬度测量和白蛋白的算法可准确预测肝细胞癌发生。
  • 推导队列和验证队列中约三分之二患者被归为低危组,肝细胞癌风险低于每年1%。

核心结论

  • 基于治疗后年龄、白蛋白、肝硬度测量,可选甲胎蛋白和饮酒量的简单算法可准确分层代偿期晚期慢性肝病患者持续病毒学应答后肝细胞癌风险。
  • 推导队列和验证队列中约三分之二患者被识别为肝细胞癌风险低于每年1%,明显低于肝细胞癌监测的成本效益阈值。

研究设计与样本

  • 推导队列纳入527例治疗前晚期慢性肝病且获得持续病毒学应答的患者,治疗前后评估甲胎蛋白和包括肝硬度测量在内的无创门脉高压替代指标。
  • 验证队列纳入来自其他欧洲中心的1500例代偿期晚期慢性肝病患者。

主要发现

  • 中位随访41个月,代偿期晚期慢性肝病患者22/475例(4.6%,1.45/100患者年)发生新发肝细胞癌,失代偿患者12/52例(23.1%,7.00/100患者年,p<0.001)。
  • 代偿期晚期慢性肝病患者中,治疗后指标对随访期间新发肝细胞癌的区分能力高于治疗前值或绝对/相对变化值。
  • 基于治疗后甲胎蛋白、饮酒量(可选)、年龄、肝硬度测量和白蛋白的模型准确预测新发肝细胞癌(bootstrapped Harrel's C:考虑饮酒0.893,不考虑饮酒0.836)。
  • 推导队列(含饮酒算法)4年肝细胞癌风险低危组0% vs 高危组16.5%,验证队列低危组3.3% vs 高危组17.5%。
  • 基于饮酒量(可选)、年龄、肝硬度测量和白蛋白(不含甲胎蛋白)的替代方法也显示稳健性能。

关键数值与推荐

  • 推导队列(含饮酒算法)低危组约三分之二患者,高危组约三分之一患者,4年肝细胞癌风险低危组0% vs 高危组16.5%。
  • 验证队列低危组肝细胞癌风险3.3% vs 高危组17.5%。
  • 推导队列和验证队列中约三分之二患者肝细胞癌风险低于每年1%。

临床怎么用

  • 基于治疗后年龄、白蛋白、肝硬度测量,可选甲胎蛋白和饮酒量的简单算法可用于分层代偿期晚期慢性肝病患者持续病毒学应答后新发肝细胞癌风险。
  • 约三分之二患者被识别为肝细胞癌风险低于每年1%,可能不需要每6个月进行肝脏超声检查。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality in patients with advanced chronic liver disease (ACLD) caused by chronic hepatitis C who have achieved sustained virologic response (SVR). We developed risk stratification algorithms for de novo HCC development after SVR and validated them in an independent cohort. METHODS: We evaluated the occurrence of de novo HCC in a derivation cohort of 527 patients with pre-treatment ACLD and SVR to interferon-free therapy, in whom alpha-fetoprotein (AFP) and non-invasive surrogates of portal hypertension including liver stiffness measurement (LSM) were assessed pre-/post-treatment. We validated our results in 1,500 patients with compensated ACLD (cACLD) from other European centers. RESULTS: During a median follow-up (FU) of 41 months, 22/475 patients with cACLD (4.6%, 1.45/100 patient-years) vs. 12/52 decompensated patients (23.1%, 7.00/100 patient-years, p <0.001) developed de novo HCC. Since decompensated patients were at substantial HCC risk, we focused on cACLD for all further analyses. In cACLD, post-treatment-values showed a higher discriminative ability for patients with/without de novo HCC development during FU than pre-treatment values or absolute/relative changes. Models based on post-treatment AFP, alcohol consumption (optional), age, LSM, and albumin, accurately predicted de novo HCC development (bootstrapped Harrel's C with/without considering alcohol: 0.893/0.836). Importantly, these parameters also provided independent prognostic information in competing risk analysis and accurately stratified patients into low- (~2/3 of patients) and high-risk (~1/3 of patients) groups in the derivation (algorithm with alcohol consumption; 4-year HCC-risk: 0% vs. 16.5%) and validation (3.3% vs. 17.5%) cohorts. An alternative approach based on alcohol consumption (optional), age, LSM, and albumin (i.e., without AFP) also showed a robust performance. CONCLUSIONS: Simple algorithms based on post-treatment age/albumin/LSM, and optionally, AFP and alcohol consumption, accurately stratified patients with cACLD based on their risk of de novo HCC after SVR. Approximately two-thirds were identified as having an HCC risk <1%/year in both the derivation and validation cohort, thereby clearly falling below the cost-effectiveness threshold for HCC surveillance. LAY SUMMARY: Simple algorithms based on age, alcohol consumption, results of blood tests (albumin and α-fetoprotein), as well as liver stiffness measurement after the end of hepatitis C treatment identify a large proportion (approximately two-thirds) of patients with advanced but still asymptomatic liver disease who are at very low risk (<1%/year) of liver cancer development, and thus, might not need to undergo 6-monthly liver ultrasound.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Semmler G, Meyer EL, Kozbial K, et al. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol. 2021. PMID: 34871626. doi:10.1016/j.jhep.2021.11.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。